Poison pills: one more reason to avoid Korea

By Cris Sholto Heaton Nov 12, 2009

Cris Sholto Heaton

Comments (3) Print this article

Korea is already famous as one of the least shareholder-friendly markets. Now investors' rights look set to take another blow, as the government mulls a daft plan to allow firms to set up 'poison pill' defences.

The 'poison pill' tactic allows a company to fight off hostile takeovers by giving existing shareholders the right to buy large numbers of new shares cheaply. The effect is to dilute hugely any stake that a bidder may try to build up.

The proposal is explicitly aimed at stopping foreign takeovers - the Korean authorities generally dislike the idea of foreigners controlling local firms.

Take US private equity firm Lone Star, which picked up a controlling stake in Korea Exchange Bank in the aftermath of the 1997-1998 Asian financial crisis. Last year, Lone Star attempted to sell the stake to HSBC. The deal would never happen, I heard at the time. Sure enough, HSBC eventually gave up after regulators kept delaying approval. Only a Korean buyer - probably Kookmin Bank - is ever likely to get clearance.

But aside from this clumsy attempt to lock out foreigners, there are other reasons for not investing in Korea. One major reason is the contempt that Korea's chaebols have for the interests of their shareholders.

Chaebols are sprawling conglomerates with multiple-listed subsidiaries and cross-shareholdings. To illustrate how large they can be, Korea has several ETFs devoted to investing in individual chaebols (including Samsung, which accounts for 20% of the Kospi benchmark index).

The complex structure of chaebols has let them shrug off any pressure to deliver better returns for shareholders, such as dividends visible to the naked eye. Promises of reform have always rung hollow, and poison pills would just confirm that.

Add in the country's other negatives, such as high debt and the risks from North Korea, and the infamous 'Korean discount' between local share valuations and the rest of Asia is fully justified.

Korea remains a market to avoid.

Comments (3)

Published in Stock markets | More articles by Cris Sholto Heaton

Share with:More

TwitterLinkedInViadeoFacebookYahoo! BuzzredditDiggDelicious

Related articles

Comments

Leave a comment

  • 1. carlos

    (12 November 2009, 11:31PM)  Complain about this comment

    Weak argument. US and Japan already allows 'posion pill'.

  • 2. Don

    (13 November 2009, 01:51AM)  Complain about this comment

    I totally Agree with Carlos. Obviously, feeding on the whole SK-NK naval propaganda. Pls.. every investor knows NK is not a threat.. Unless your voyuer looking from the outside...

  • 3. Cris Sholto Heaton

    (13 November 2009, 02:27PM)  Complain about this comment

    Thanks for the counterpoints.

    Yes, I had mentioned US and Japan poison pills, but I think that was removed to save space. It's not helpful there either. The difference is that the US doesn’t have value-destroying conglomerates anymore, although it has plenty of areas where treatment of shareholders could improve. Japan has the keiretsu, but they don't dominate the large-cap space and thus most funds like the chaebol do in Korea.

    The issue is not the poison pill law as such, it's the way it illustrates again how little large Korean firms care for shareholders and suggests talk of reforms will remain just that. If I were investing in Korea (and I’m not), I'd favour small-cap funds.

    I don’t think we can overlook the North Korean issue. I’m not just referring to the military threat; when the regime falls, the reunification process will be a drag on the south for years. Think how East Germany affected West Germany and bear in mind that the gulf between the Koreas is far greater.

Leave a comment

This will be the name displayed with your comment.

This helps us verify comments are genuine. It will not be displayed anywhere on the site and is stored confidentially.

Please keep your comment to within 1,000 characters, and relevant to the main topic. Comments not directly on topic will be removed.

captcha To prevent spam-related comments please enter the characters shown in the CAPTCHA box to the left.

By leaving a comment you accept our terms and conditions.


FREE - MoneyWeek's daily investment emailJohn Stepek

Our free daily email, Money Morning, is an informative and enjoyable analysis of what's going on in the markets. Written by our Editor, John Stepek, and guest contributors.
Sign up FREE to Money Morning here.